All lobbying filings

TIBER CREEK GROUP

Lobbying for TAKEDA PHARMACEUTICALS AMERICA, INC. · Pharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 18, 2026

Official filing document

Bills named in this filing 1

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Health Issues

Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.